The relationship between erectile dysfunction and serum adropin level in male patients with type 2 diabetes mellitus
Abstract
Background: Diabetes Mellitus is a chronic, progressive disease with increasing worldwide prevalence and is a public health problem because of the high cost of treatment and complications. Adropin has been discovered in recent years, and it has been reported to be associated with glucose, lipid metabolism, and endothelial dysfunction. In this study, it was aimed to investigate the relationship between erectile dysfunction and Adropin level in Type 2 diabetic male patients.
Methods: Forty patients with type 2 DM with erectile dysfunction and 25 patients with type 2 DM without erectile dysfunction, aged between 40 and 60, who applied to the internal medicine outpatient clinic between November 2019 and March 2020, were included in the prospective study. In addition to routine blood tests in the study groups, Adropin levels were measured using the ELISA method.
Results: The study was conducted with 65 men aged 40 and 60 between November 2019 and February 2020. The mean age of the men was 52.71±6.04. The study used 40 (61.5%) Case groups and 25 (38.5%) Control groups. The case group consisted of 12 (18.5%) Mild ED, 20 (30.8%) Moderate ED, and 8 (12.8%) Severe ED, and the control group consisted of Type 2 Diabetes Mellitus Patients without erectile dysfunction.
Conclusion: According to our results, serum Adropin levels in Mild ED, Moderate ED, and Severe ED groups were found to be higher than those in Type 2 Diabetes Mellitus patients without erectile dysfunction.
Keywords
References
- Zimmet P, Williams J, de Courten M. Diagnosis and classification 1. of diabetes mellitus. Wass JAM, Shalet SM, Gale E, Amiel S. (Eds). Oxford Textbook of Endocrinology and Diabetes. Oxford, New York: Oxford University Press. 2014; 1635- 1646.
- International Diabetes Federation. Diabetes Atlas, 6th Edition, 2013.
- Sekikawa A, LaPorte RE. Epidemiology of insulin-dependent diabetes mellitus. KGMM Alberti, P Zimmet, RA DeFronzo, H Keen (Eds), International Textbook of Diabetes Mellitus, 2nd Ed. Volume I, New York: John Wiley & Sons Ltd. 1997; 89-96.
- Green A, Sjølie AK, Eshøj O. Trends in the epidemiology of IDDM during 1970-2020 in Fyn County, Denmark. Diabetes Care. 1996 Aug;19(8):801-6. doi: 10.2337/diacare.19.8.801.
- International Diabetes Federation. World Diabetes Foundation. Diabetes Atlas. 2nd Edition, Brussels, International Diabetes Federation, 2003.
- Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, Kousoulas KG, Rogers PM, Kesterson RA, Thearle M, Ferrante AW Jr, Mynatt RL, Burris TP, Dong JZ, Halem HA, Culler MD, Heisler LK, Stephens JM, Butler AA. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008 Dec;8(6):468-81. doi: 10.1016/j.cmet.2008.10.01.
- Kuloglu T, Aydin S. Immunohistochemical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech Histochem. 2014 Feb;89(2):104-10. doi: 10.3109/10520295.2013.821713.
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993 Jul 7;270(1):83-90.
- Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol. 1996 Dec;156(6):2007-11. doi: 10.1016/s0022-5347(01)65419-3.
- Wagner G, Saenz de Tejada I. Update on male erectile dysfunction. BMJ. 1998 Feb 28;316(7132):678-82. doi: 10.1136/bmj.316.7132.678.